# FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

> **NCT05077800** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Colin D. Weekes, M.D., PhD** · enrollment: 70 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic

## Interventions

- **DRUG:** FOLFIRNINOX
- **DRUG:** Losartan
- **DRUG:** 9-ING-41

## Key facts

- **NCT ID:** NCT05077800
- **Lead sponsor:** Colin D. Weekes, M.D., PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077800, "FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05077800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*